KVP Capital Advisors, LP
13F Reported Value
ⓘ$136.2M
Holdings
35
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
KVP Capital Advisors, LP disclosed 35 positions worth $136.2M in its Form 13F-HR for Q2 2026, led by $PRAX (Praxis Precision Medicines, Inc.) at 10.5% of the equity portfolio, followed by $WHWK and $ERAS. During the quarter the fund opened 6 new positions and exited 3 — including a new stake in $TNDM and a full exit from $TERN. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from KVP Capital Advisors, LP’s Form 13F-HR filing with the SEC under CIK 1858198.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $14.4M42,900 sh
- 26.4#2,729
Quality
$9.9M2,165,997 sh - —
Quality
$8.3M455,000 sh - —
Quality
$7.7M414,000 sh - 15.3
Quality
$7.5M226,575 sh - 17.6
Quality
$7.2M230,264 sh - —
Quality
$6.7M121,524 sh - 59.4
Quality
$6.5M53,000 sh - —
Quality
$5.4M133,000 sh - 42.8
Quality
$4.5M301,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $14.4M | 42,900 |
 Whitehawk Therapeutics, Inc.$WHWK | 26.4#2,729 | $9.9M | 2,165,997 |
 Erasca, Inc.$ERAS | — | $8.3M | 455,000 |
 Trevi Therapeutics, Inc.$TRVI | — | $7.7M | 414,000 |
 SUTRO BIOPHARMA, INC.$STRO | 15.3 | $7.5M | 226,575 |
 Tango Therapeutics, Inc.$TNGX | 17.6 | $7.2M | 230,264 |
 MBX Biosciences, Inc.$MBX | — | $6.7M | 121,524 |
 Protagonist Therapeutics, Inc$PTGX | 59.4 | $6.5M | 53,000 |
 Edgewise Therapeutics, Inc.$EWTX | — | $5.4M | 133,000 |
 TANDEM DIABETES CARE INC$TNDM | 42.8 | $4.5M | 301,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of KVP Capital Advisors, LP's 35 positions.
Showing top 10 of 35 holdings.
Sector Allocation
Healthcare
$136.2M
Full Holdings — KVP Capital Advisors, LP (Q2 2026)
All 35 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $14.4M | 10.5% | +0% | — |
| 2 | $WHWK | Whitehawk Therapeutics, Inc. | $9.9M | 7.3% | +0% | 26.4 |
| 3 | $ERAS | Erasca, Inc. | $8.3M | 6.1% | +34% | — |
| 4 | $TRVI | Trevi Therapeutics, Inc. | $7.7M | 5.7% | +0% | — |
| 5 | $STRO | SUTRO BIOPHARMA, INC. | $7.5M | 5.5% | +0% | 15.3 |
| 6 | $TNGX | Tango Therapeutics, Inc. | $7.2M | 5.3% | +0% | 17.6 |
| 7 | $MBX | MBX Biosciences, Inc. | $6.7M | 4.9% | +0% | — |
| 8 | $PTGX | Protagonist Therapeutics, Inc | $6.5M | 4.8% | +0% | 59.4 |
| 9 | $EWTX | Edgewise Therapeutics, Inc. | $5.4M | 4.0% | +0% | — |
| 10 | $TNDM | TANDEM DIABETES CARE INC | $4.5M | 3.3% | NEW | 42.8 |
| 11 |  $IRON | Disc Medicine, Inc. | $4.3M | 3.1% | +0% | — |
| 12 |  $SVRA | Savara Inc | $3.7M | 2.7% | +0% | — |
| 13 |  $AVBP | ArriVent BioPharma, Inc. | $3.5M | 2.6% | NEW | — |
| 14 |  $INSM | INSMED Inc | $3.0M | 2.2% | +0% | 39.4 |
| 15 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $3.0M | 2.2% | +0% | — |
| 16 |  $IDYA | IDEAYA Biosciences, Inc. | $3.0M | 2.2% | +0% | 36.1 |
| 17 |  $OCUL | OCULAR THERAPEUTIX, INC | $2.9M | 2.2% | +0% | 8.4 |
| 18 |  $AXSM | Axsome Therapeutics, Inc. | $2.9M | 2.2% | -67% | 40.8 |
| 19 |  $DSGN | Design Therapeutics, Inc. | $2.7M | 2.0% | NEW | — |
| 20 |  $UTHR | UNITED THERAPEUTICS Corp | $2.6M | 1.9% | +0% | 71.3 |
| 21 |  $SRRK | Scholar Rock Holding Corp | $2.5M | 1.8% | +0% | — |
| 22 |  $IMMX | Immix Biopharma, Inc. | $2.4M | 1.7% | +0% | — |
| 23 |  $VRDN | Viridian Therapeutics, Inc.\DE | $2.3M | 1.7% | +0% | 27.2 |
| 24 |  $MLYS | Mineralys Therapeutics, Inc. | $2.3M | 1.7% | NEW | — |
| 25 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $2.2M | 1.6% | +0% | — |
| 26 |  $TVTX | Travere Therapeutics, Inc. | $2.2M | 1.6% | -57% | 56.6 |
| 27 |  $ZURA | Zura Bio Ltd | $2.2M | 1.6% | +0% | — |
| 28 |  $ARTV | Artiva Biotherapeutics, Inc. | $1.9M | 1.4% | NEW | 9.7 |
| 29 |  $NKTR | NEKTAR THERAPEUTICS | $1.9M | 1.4% | +0% | 9.7 |
| 30 |  $CMPX | Compass Therapeutics, Inc. | $1.7M | 1.2% | +54% | 28.1 |
| 31 |  $CABA | Cabaletta Bio, Inc. | $1.6M | 1.1% | +0% | — |
| 32 |  $VERA | Vera Therapeutics, Inc. | $1.4M | 1.0% | +0% | — |
| 33 |  $EOLS | Evolus, Inc. | $1.0M | 0.8% | NEW | 39 |
| 34 |  $CELC | Celcuity Inc. | $418,480 | 0.3% | +0% | — |
| 35 |  $YARW | Yarrow Bioscience, Inc. | $325,709 | 0.2% | +0% | — |
New Positions (6)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for KVP Capital Advisors, LP including:
Track KVP Capital Advisors, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for KVP Capital Advisors, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: KVP Capital Advisors, LP
13F Pro is an AI hedge fund tracker and stock research platform. For KVP Capital Advisors, LP (SEC CIK: 1858198), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in KVP Capital Advisors, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.